Clinical Trial Update: PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of PTK787/ZK 222584 (vatalanib) for unresectable malignant mesothelioma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma

Drugs mentioned

• PTK787/ZK 222584 (vatalanib) (vatalanib)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Malignant Mesothelioma | Phase 2 | Status: COMPLETED